AAPL342.00-0.96 (-0.28%) ▼|ABBV283.40+1.65 (+0.59%) ▲|ABT104.68+2.34 (+2.29%) ▲|ACN224.92+9.96 (+4.63%) ▲|ADBE251.67+10.99 (+4.57%) ▲|AMAT430.01-16.62 (-3.72%) ▼|AMD562.23-8.59 (-1.50%) ▼|AMGN434.03+7.92 (+1.86%) ▲|AMT181.36+1.96 (+1.09%) ▲|AMZN254.76+0.68 (+0.27%) ▲|AVGO344.33-1.92 (-0.55%) ▼|AXP313.87+6.92 (+2.25%) ▲|BA188.73+4.07 (+2.20%) ▲|BAC51.70+0.31 (+0.60%) ▲|BKNG165.80+5.12 (+3.19%) ▲|BLK1,120.78+46.99 (+4.38%) ▲|BMY60.57+1.29 (+2.18%) ▲|BNY142.09+4.45 (+3.23%) ▲|BRK-B525.68-0.67 (-0.13%) ▼|C123.21+0.94 (+0.77%) ▲|CAT735.64-13.34 (-1.78%) ▼|CL92.67-0.11 (-0.12%) ▼|CMCSA21.77+0.72 (+3.42%) ▲|COF198.86+4.51 (+2.32%) ▲|COP141.73-0.61 (-0.43%) ▼|COST978.01-3.99 (-0.41%) ▼|CRM246.74+10.79 (+4.57%) ▲|CSCO109.85-3.79 (-3.34%) ▼|CVS92.58+2.19 (+2.42%) ▲|CVX219.32-2.72 (-1.23%) ▼|DE650.67+0.29 (+0.04%) ▲|DHR231.50+6.81 (+3.03%) ▲|DIS110.68+1.69 (+1.55%) ▲|DUK118.88-0.76 (-0.64%) ▼|EMR162.15+1.07 (+0.66%) ▲|FDX295.54+4.26 (+1.46%) ▲|GD337.03+2.37 (+0.71%) ▲|GE312.00+4.98 (+1.62%) ▲|GEV926.44-15.34 (-1.63%) ▼|GILD157.37+3.83 (+2.49%) ▲|GM83.66+0.61 (+0.73%) ▲|GOOG344.91+1.26 (+0.37%) ▲|GOOGL349.22+1.58 (+0.45%) ▲|GS891.28+12.56 (+1.43%) ▲|HD308.24+12.73 (+4.31%) ▲|HON210.50+2.89 (+1.39%) ▲|IBM234.12+6.24 (+2.74%) ▲|INTC95.37-2.75 (-2.80%) ▼|INTU330.17+19.73 (+6.36%) ▲|ISRG427.86+7.62 (+1.81%) ▲|JNJ253.28-0.63 (-0.25%) ▼|JPM335.53+0.25 (+0.07%) ▲|KO92.00+0.22 (+0.24%) ▲|LIN493.22+0.52 (+0.11%) ▲|LLY1,251.61+42.87 (+3.55%) ▲|LMT532.64+10.41 (+1.99%) ▲|LOW195.72+7.41 (+3.94%) ▲|LRCX277.46-9.46 (-3.30%) ▼|MA616.32+13.08 (+2.17%) ▲|MCD242.50+4.19 (+1.76%) ▲|MDLZ63.03+0.46 (+0.74%) ▲|MDT95.45+1.22 (+1.29%) ▲|META736.72-0.82 (-0.11%) ▼|MMM165.33+0.87 (+0.53%) ▲|MO73.84+0.71 (+0.97%) ▲|MRK145.19-2.18 (-1.48%) ▼|MS182.10+0.59 (+0.33%) ▲|MSFT539.44+5.75 (+1.08%) ▲|MU931.24+17.11 (+1.87%) ▲|NEE78.96+0.59 (+0.75%) ▲|NFLX72.61+2.04 (+2.89%) ▲|NKE37.14+1.84 (+5.21%) ▲|NOW148.57+8.59 (+6.14%) ▲|NVDA217.23-4.07 (-1.84%) ▼|ORCL134.47+3.92 (+3.00%) ▲|PEP128.38-0.89 (-0.69%) ▼|PFE29.44+0.23 (+0.79%) ▲|PG157.08+0.55 (+0.35%) ▲|PLTR200.50-0.47 (-0.23%) ▼|PM199.90-5.68 (-2.76%) ▼|QCOM178.40+5.78 (+3.35%) ▲|RTX186.95+0.48 (+0.26%) ▲|SBUX96.88+3.63 (+3.89%) ▲|SCHW94.16-2.64 (-2.73%) ▼|SO89.18-0.20 (-0.22%) ▼|SPG203.39+4.69 (+2.36%) ▲|T23.50+0.45 (+1.95%) ▲|TMO696.49+23.29 (+3.46%) ▲|TMUS157.03-0.76 (-0.48%) ▼|TSLA362.44-4.72 (-1.29%) ▼|TXN279.12-1.53 (-0.55%) ▼|UBER71.27+1.98 (+2.86%) ▲|UNH406.67+11.05 (+2.79%) ▲|UNP288.71+2.28 (+0.80%) ▲|UPS97.83+2.05 (+2.14%) ▲|USB57.39+1.13 (+2.01%) ▲|V399.75+8.32 (+2.13%) ▲|VZ44.40-0.02 (-0.05%) ▼|WFC82.75+1.85 (+2.29%) ▲|WMT117.87+1.71 (+1.47%) ▲|XOM174.68-2.33 (-1.32%) ▼|AAPL342.00-0.96 (-0.28%) ▼|ABBV283.40+1.65 (+0.59%) ▲|ABT104.68+2.34 (+2.29%) ▲|ACN224.92+9.96 (+4.63%) ▲|ADBE251.67+10.99 (+4.57%) ▲|AMAT430.01-16.62 (-3.72%) ▼|AMD562.23-8.59 (-1.50%) ▼|AMGN434.03+7.92 (+1.86%) ▲|AMT181.36+1.96 (+1.09%) ▲|AMZN254.76+0.68 (+0.27%) ▲|AVGO344.33-1.92 (-0.55%) ▼|AXP313.87+6.92 (+2.25%) ▲|BA188.73+4.07 (+2.20%) ▲|BAC51.70+0.31 (+0.60%) ▲|BKNG165.80+5.12 (+3.19%) ▲|BLK1,120.78+46.99 (+4.38%) ▲|BMY60.57+1.29 (+2.18%) ▲|BNY142.09+4.45 (+3.23%) ▲|BRK-B525.68-0.67 (-0.13%) ▼|C123.21+0.94 (+0.77%) ▲|CAT735.64-13.34 (-1.78%) ▼|CL92.67-0.11 (-0.12%) ▼|CMCSA21.77+0.72 (+3.42%) ▲|COF198.86+4.51 (+2.32%) ▲|COP141.73-0.61 (-0.43%) ▼|COST978.01-3.99 (-0.41%) ▼|CRM246.74+10.79 (+4.57%) ▲|CSCO109.85-3.79 (-3.34%) ▼|CVS92.58+2.19 (+2.42%) ▲|CVX219.32-2.72 (-1.23%) ▼|DE650.67+0.29 (+0.04%) ▲|DHR231.50+6.81 (+3.03%) ▲|DIS110.68+1.69 (+1.55%) ▲|DUK118.88-0.76 (-0.64%) ▼|EMR162.15+1.07 (+0.66%) ▲|FDX295.54+4.26 (+1.46%) ▲|GD337.03+2.37 (+0.71%) ▲|GE312.00+4.98 (+1.62%) ▲|GEV926.44-15.34 (-1.63%) ▼|GILD157.37+3.83 (+2.49%) ▲|GM83.66+0.61 (+0.73%) ▲|GOOG344.91+1.26 (+0.37%) ▲|GOOGL349.22+1.58 (+0.45%) ▲|GS891.28+12.56 (+1.43%) ▲|HD308.24+12.73 (+4.31%) ▲|HON210.50+2.89 (+1.39%) ▲|IBM234.12+6.24 (+2.74%) ▲|INTC95.37-2.75 (-2.80%) ▼|INTU330.17+19.73 (+6.36%) ▲|ISRG427.86+7.62 (+1.81%) ▲|JNJ253.28-0.63 (-0.25%) ▼|JPM335.53+0.25 (+0.07%) ▲|KO92.00+0.22 (+0.24%) ▲|LIN493.22+0.52 (+0.11%) ▲|LLY1,251.61+42.87 (+3.55%) ▲|LMT532.64+10.41 (+1.99%) ▲|LOW195.72+7.41 (+3.94%) ▲|LRCX277.46-9.46 (-3.30%) ▼|MA616.32+13.08 (+2.17%) ▲|MCD242.50+4.19 (+1.76%) ▲|MDLZ63.03+0.46 (+0.74%) ▲|MDT95.45+1.22 (+1.29%) ▲|META736.72-0.82 (-0.11%) ▼|MMM165.33+0.87 (+0.53%) ▲|MO73.84+0.71 (+0.97%) ▲|MRK145.19-2.18 (-1.48%) ▼|MS182.10+0.59 (+0.33%) ▲|MSFT539.44+5.75 (+1.08%) ▲|MU931.24+17.11 (+1.87%) ▲|NEE78.96+0.59 (+0.75%) ▲|NFLX72.61+2.04 (+2.89%) ▲|NKE37.14+1.84 (+5.21%) ▲|NOW148.57+8.59 (+6.14%) ▲|NVDA217.23-4.07 (-1.84%) ▼|ORCL134.47+3.92 (+3.00%) ▲|PEP128.38-0.89 (-0.69%) ▼|PFE29.44+0.23 (+0.79%) ▲|PG157.08+0.55 (+0.35%) ▲|PLTR200.50-0.47 (-0.23%) ▼|PM199.90-5.68 (-2.76%) ▼|QCOM178.40+5.78 (+3.35%) ▲|RTX186.95+0.48 (+0.26%) ▲|SBUX96.88+3.63 (+3.89%) ▲|SCHW94.16-2.64 (-2.73%) ▼|SO89.18-0.20 (-0.22%) ▼|SPG203.39+4.69 (+2.36%) ▲|T23.50+0.45 (+1.95%) ▲|TMO696.49+23.29 (+3.46%) ▲|TMUS157.03-0.76 (-0.48%) ▼|TSLA362.44-4.72 (-1.29%) ▼|TXN279.12-1.53 (-0.55%) ▼|UBER71.27+1.98 (+2.86%) ▲|UNH406.67+11.05 (+2.79%) ▲|UNP288.71+2.28 (+0.80%) ▲|UPS97.83+2.05 (+2.14%) ▲|USB57.39+1.13 (+2.01%) ▲|V399.75+8.32 (+2.13%) ▲|VZ44.40-0.02 (-0.05%) ▼|WFC82.75+1.85 (+2.29%) ▲|WMT117.87+1.71 (+1.47%) ▲|XOM174.68-2.33 (-1.32%) ▼|
17.3 C
New York
Friday, October 16, 2026

Tag: clinical trials

newssourceFORcompanycontentinformation1releasesmarket

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology,...

Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates

NEW TAIPEI CITY, Oct. 16, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026

Findings from the Phase 3 LITESPARK-011 and LITESPARK-012 studies reflect continued research into LENVIMA® (lenvatinib)-based combination regimens for patients with advanced renal cell carcinomaExploratory...

Virginia Cancer Specialists Celebrates Expansion in New Fauquier Location, Improving Access to Comprehensive Cancer Care and Future Clinical Research Opportunities

FAUQUIER COUNTY, Va., Oct. 15, 2026 /PRNewswire/ -- Virginia Cancer Specialists, the Commonwealth's leading cancer care practice, is proud to announce the grand opening...

Saving Heart Muscle After a Heart Attack: Nature Reports PeriFlow’s First-in-Class Capillary-Selective Vasodilator

PeriFlow Therapeutics is advancing CLN-2501, a first-in-class drug candidate designed to restore capillary blood flow after Acute Myocardial Infarction by targeting a newly-druggable mechanism...

Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care

FCS Clinical Research Continues to Pave the Way for Breakthrough TreatmentsFORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute,...

TRI Introduces AI-driven Risk Assessment and Connected Oversight in Latest OPRA Release

CAMBRIDGE, England, Oct. 14, 2026 /PRNewswire/ -- TRI has announced the latest release of OPRA, its risk-based quality management (RBQM) platform. The release introduces...

Cumulus Neuroscience and Transpharmation Partner to Carry Objective EEG Measurement from Preclinical Research into First-in-Human Studies

The two companies will work jointly with biopharma sponsors to provide a bridge between pre-clinical work and first-in-human studies, aligning quantitative EEG and cognitive...

TRI Introduces AI-driven Risk Assessment and Connected Oversight in Latest OPRA Release

CAMBRIDGE, England, Oct. 14, 2026 /PRNewswire/ -- TRI has announced the latest release of OPRA, its risk-based quality management (RBQM) platform. The release introduces...

Danaher Collaborates with NVIDIA to Advance Autonomous Science

Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and dataWASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR)...

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will...

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation |...

The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001;...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers